Otitis Media – Global Clinical Trials Review, H2, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData’s clinical trial report provides an overview of the otitis media clinical trials scenario. This report provides top-line data relating to the clinical trials on otitis media. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress trials (based on several ongoing trials). GlobalData clinical trial reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news, etc across the globe. Clinical trials database undergoes periodic updates by dynamic process.
Otitis Media clinical trial report consists of 881 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, Phase I, and Phase 0 stand at 39, 63, 45, 577, and 1 respectively. Similarly, the trials with different status compile of completed – 616, ongoing – 65, planned – 112, suspended – 6, terminated – 17, and withdrawn – 65. Out of 616 completed trials 223 trials have achieved endpoint.
What are the market dynamics of the global otitis media therapeutics clinical trials sector?
The number of otitis media clinical trials conducted globally has increased by over 600% for the period 2016-2020. As of December 2021, out of 616 completed trials, 262 trials have results and 223 trials reached endpoints. There were 592 clinical trials in Phase I, of which 35 clinical trials were in progress for the time period 1995-2021. During the same period, there were 65 clinical trials in progress and 616 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 88.
What are the top regions and countries in the global otitis media therapeutics clinical trials sector?
In total there were 881 clinical trials conducted on otitis media, as of December 2021, of these 507 clinical trials were in Asia-Pacific. During the same period, China has the highest average patient enrollment in otitis media clinical trials.
Asia-Pacific: In the Asia-Pacific region, China has the highest number of otitis media clinical trials followed by India, Japan, South Korea, and Malaysia.
Europe: Among the European countries, Russia has the highest number of otitis media clinical trials followed by the UK, Czech Republic, the Netherlands, and Finland.
North America: The US has the highest number of otitis media clinical trials followed by Canada and Mexico.
Middle East and Africa: Iran has the highest number of otitis media clinical trials followed by Israel, South Africa, Jordan, and the United Arab Emirates.
South and Central America: Costa Rica has the highest number of otitis media clinical trials followed by Chile, Guatemala, the Dominican Republic, and Argentina.
G7 countries: Among the G7 (The US, the UK Germany, France, Italy, Canada, and Japan) countries, Japan has the highest proportion of otitis media to ear nose throat disorders clinical trials as of December 2021. In total there were 170 clinical trials conducted on otitis media, in G7 countries, of these 90 clinical trials were in the US. During the same period, there were seven clinical trials in progress and 134 trials are completed. The trials that are terminated/suspended or withdrawn accounted for 16.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Indonesia has the highest proportion of otitis media to ear nose throat disorders clinical trials as of December 2021. There were 469 clinical trials conducted on otitis media, in E7 countries, of these 355 clinical trials were in China. During the same period, there were 42 clinical trials in progress and 295 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 45.
Global otitis media therapeutics clinical trials sector, by regions
For more regional insights, download a free report sample
Which are the key companies in the global otitis media therapeutics clinical trials sector?
As of December 2021, GlaxoSmithKline Plc sponsored the highest number of otitis media clinical trials followed by Novartis AG and Pfizer Inc. Other major companies in the sector are Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd, Genefar BV, North China Pharmaceutical Co Ltd, Harbin Pharmaceutical Group Co Ltd, China National Pharmaceutical Group Corp, Alcon Inc, and Abbott Laboratories.
Global otitis media therapeutics clinical trials sector, by key companies
To know more about key companies, download a free report sample
Market report scope
Key countries | The US, China, Russia, India, Japan, South Korea, Iran, Canada, Malaysia, and Finland |
Key companies | GlaxoSmithKline Plc, Novartis AG, Pfizer Inc, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd, Genefar BV, North China Pharmaceutical Co Ltd, Harbin Pharmaceutical Group Co Ltd, China National Pharmaceutical Group Corp, Alcon Inc, and Abbott Laboratories. |
Scope
- The report provides a snapshot of the global clinical trials landscape.
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End point status.
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
- The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with the reason for unaccomplishment.
- The Report provides enrollment trends for the past five years.
- Report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country-level.
Novartis AG
Pfizer Inc
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Genefar BV
North China Pharmaceutical Co Ltd
Alcon Inc
China National Pharmaceutical Group Corp
Harbin Pharmaceutical Group Co Ltd
Abbott Laboratories
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key countries in the global otitis media therapeutics clinical trials sector?
Key countries in the global otitis media therapeutics clinical trials sector are the US, China, Russia, India, Japan, South Korea, Iran, Canada, Malaysia, and Finland.
-
Which are the key companies in the global otitis media therapeutics clinical trials sector?
Key companies in the global otitis media therapeutics clinical trials sector are GlaxoSmithKline Plc, Novartis AG, Pfizer Inc, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd, Genefar BV, North China Pharmaceutical Co Ltd, Harbin Pharmaceutical Group Co Ltd, China National Pharmaceutical Group Corp, Alcon Inc, and Abbott Laboratories.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Ear Nose Throat Disorders reportsOtitis Media – Global Clinical Trials Review, H1, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData's clinical trial report, “Otitis Media – Global Clinical Trials Review, H1, 2021" provides an overview of Otitis Media Clinical trials scenario. This report provides top line data relating to the clinical trials on Otitis Media. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to Buy
– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Novartis AG
Pfizer Inc
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Genefar BV
Alcon Inc
Harbin Pharmaceutical Group Co Ltd
North China Pharmaceutical Co Ltd
Abbott Laboratories
Bain Capital Private Equity LP
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.